- $525.25m
- $513.94m
- $0.04m
Corrected: Israel's Entera Bio Q2 net loss widens
NASDAQ RESUMED AT 10:02 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:57 AM
Brief: Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement
NASDAQ RESUMED AT 12:27 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:17 PM
Brief: Entera Bio Submits Streamlined Phase 3 Protocol To Initiate Registrational Program For Eb613 In Postmenopausal Women With Osteoporosis
Brief: Entera Bio Announces Open Market Purchases Of Company Stock By Board Members
Brief: Entera Bio Appoints Former Pfizer Executive Geno J. Germano As Chairman Of The Board Ahead Of Key Milestones
Brief: Entera Bio Ltd Geno J. Germano Appointed As Chairman Of Entera Bio
Brief: Opko Health And Entera Bio Expand Partnership To Advance First-In-Class Oral Long Acting Pth Tablet For Patients With Hypoparathyroidism
Israel's Entera Bio Q3 net loss widens
Brief: Entera Bio Reports Positive PK Data For Oral GLP-2 Tablet For Short Bowel Syndrome At 2025 ESPEN Congress
Entera Bio Ltd expected to post a loss of 11 cents a share - Earnings Preview
Entera Bio Ltd expected to post a loss of 11 cents a share - Earnings Preview
Brief: Entera Bio Receives FDA Agreement On Bmd As Primary Endpoint For Eb613 Registrational, Phase 3 Study In Post-Menopausal Women With Osteoporosis
Brief: Entera Bio Enters Sales Agreement, May Offer & Sell Up To 30 Million Ordinary Shares
Entera Bio Ltd expected to post a loss of 7 cents a share - Earnings Preview
Entera Bio Ltd reports results for the quarter ended December 31 - Earnings Summary